Viking Therapeutics, Inc. (VKTX): Revenue
$0
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | n/a | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $0 | n/a | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $0 | n/a | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $0 | n/a | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $0 | n/a | 2024-02-07, From 2021-01-01 |
| 2020-12-31 | $0 | n/a | 2022-02-09, From 2020-01-01 |
| 2019-12-31 | $0 | n/a | 2021-02-17, From 2019-01-01 |
| 2018-12-31 | $0 | n/a | 2020-02-26, From 2018-01-01 |
| 2017-12-31 | $0 | n/a | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | $0 | n/a | 2018-03-07, From 2016-01-01 |
| 2015-12-31 | $0 | n/a | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | $0 | n/a | 2016-03-08, From 2014-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $0 | n/a |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $3.02M | +71.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $480.14M | +5.7% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
Compare VKTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗